Effect of low dose pioglitazone on glycemic control and insulin resistance in Type 2 diabetes: A randomized, double blind, clinical trial

Diabetes Res Clin Pract. 2015 Sep;109(3):e32-5. doi: 10.1016/j.diabres.2015.05.030. Epub 2015 May 15.

Abstract

This study shows that pioglitazone 7.5 mg/day as an add-on therapy in Southeast Asian patients with Type 2 diabetes is safer and equally efficacious as the 15- and 30-mg doses of pioglitazone. Hence it is prudent to start pioglitazone therapy at a lower dose of 7.5 mg/day.

Keywords: Insulin resistance; Low dose; Pioglitazone; Thiazolidinediones; Type 2 diabetes.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Asia, Southeastern / epidemiology
  • Asian People
  • Blood Glucose / drug effects*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / epidemiology
  • Diabetes Mellitus, Type 2 / metabolism
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Glycated Hemoglobin / analysis
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Insulin Resistance*
  • Lipids / blood
  • Male
  • Middle Aged
  • Pioglitazone
  • Thiazolidinediones / administration & dosage*

Substances

  • Blood Glucose
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Lipids
  • Thiazolidinediones
  • Pioglitazone